We are live on !
Find out more
Commodore Capital Portfolio holdings
AUM
$1.68B
Turnover
31.71%
1-Year Est. Return
375.52%
This Fund
S&P 500
This Quarter Est. Return
+40.89%
1 Year Est. Return
+375.52%
3 Year Est. Return
+2,120.72%
5 Year Est. Return
+8,694.03%
10 Year Est. Return
–
AUM
$1.68B
AUM Growth
-$49.5M
(-2.9%)
Cap. Flow
-$478M
Cap. Flow % of AUM
Cap. Flow %
-28.49%
Top 10 Holdings %
Top 10 Hldgs %
68.18%
Holding
41
New
5
Increased
6
Reduced
9
Closed
8
Avg Time Held
1.1
years
Top 10 Avg Time Held
0.7
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tango Therapeutics
TNGX
|
+$55.6M |
| 2 |
Editas Medicine
EDIT
|
+$26M |
| 3 |
EyePoint Inc
EYPT
|
+$23.7M |
| 4 |
InflaRx
IFRX
|
+$13.7M |
| 5 |
Assembly Biosciences
ASMB
|
+$11.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nuvalent
NUVL
|
+$78.9M |
| 2 |
Spyre Therapeutics
SYRE
|
+$77.8M |
| 3 |
Relay Therapeutics
RLAY
|
+$72.6M |
| 4 |
Erasca
ERAS
|
+$51.4M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.36% |
| 2 | Financials | 0.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Relay Therapeutics
RLAY
$3.98B
| $225M | 13.37% |
12,000,000
-5,000,000
| -29% | -$72.6M |
2025 Q2
4 quarters
|
|
2
Enliven Therapeutics
ELVN
$3.04B
| $166M | 9.9% |
3,275,000
| – | – |
2022 Q4
14 quarters
|
|
3
Alkermes
ALKS
$7.32B
| $157M | 9.36% |
3,000,000
-1,200,000
| -29% | -$46.9M |
2024 Q2
8 quarters
|
|
4
Cogent Biosciences
COGT
$5.42B
| $118M | 7.03% |
3,050,000
+161,993
| +6% | +$5.67M |
2020 Q4
22 quarters
|
|
5
Amylyx Pharmaceuticals
AMLX
$3.41B
| $101M | 6.04% |
5,650,000
| – | – |
2025 Q3
3 quarters
|
|
6
Definium Therapeutics
DFTX
$4.79B
| $94.1M | 5.6% |
2,000,000
| – | – |
2024 Q1
9 quarters
|
|
|
7
Spyre Therapeutics
SYRE
$8.44B
| $75.2M | 4.48% |
846,786
-1,065,594
| -56% | -$77.8M |
2023 Q2
12 quarters
|
|
8
Alto Neuroscience
ANRO
$862M
| $71.9M | 4.28% |
2,723,196
| – | – |
2025 Q4
2 quarters
|
|
|
9
Tango Therapeutics
TNGX
$3.94B
| $70.3M | 4.19% |
+2,250,000
| New | +$55.6M |
2026 Q2
0 quarters
|
|
|
10
EyePoint Inc
EYPT
$34.9M
| $65.8M | 3.92% |
4,600,000
+1,775,000
| +63% | +$23.7M |
2026 Q1
1 quarter
|
|
11
Tyra Biosciences
TYRA
$1.41B
| $59.9M | 3.57% |
1,875,000
-600,000
| -24% | -$19.8M |
2025 Q1
5 quarters
|
|
|
DMRA
12
Damora Therapeutics
DMRA
$1.3B
| $50.4M | 3% |
1,939,000
| – | – |
2026 Q1
1 quarter
|
|
13
Celldex Therapeutics
CLDX
$2.3B
| $50.2M | 2.99% |
1,350,000
-1,346,616
| -50% | -$43.5M |
2025 Q1
5 quarters
|
|
14
Pharvaris
PHVS
$2.21B
| $49.3M | 2.93% |
1,425,000
-493,970
| -26% | -$14.9M |
2023 Q4
10 quarters
|
|
15
LB Pharmaceuticals
LBRX
$1.25B
| $48.7M | 2.9% |
1,500,000
| – | – |
2025 Q3
3 quarters
|
|
|
16
Assembly Biosciences
ASMB
$404M
| $38.9M | 2.32% |
1,415,000
+415,000
| +42% | +$11.3M |
2025 Q3
3 quarters
|
|
|
17
Editas Medicine
EDIT
$369M
| $28.8M | 1.72% |
+8,889,000
| New | +$26M |
2026 Q2
0 quarters
|
|
18
Kymera Therapeutics
KYMR
$9.21B
| $28.7M | 1.71% |
250,000
-500,000
| -67% | -$43M |
2025 Q2
4 quarters
|
|
19
Perspective Therapeutics
CATX
$184M
| $21.6M | 1.29% |
6,336,782
| – | – |
2026 Q1
1 quarter
|
|
20
Century Therapeutics
IPSC
$264M
| $21.3M | 1.27% |
8,695,652
| – | – |
2026 Q1
1 quarter
|
|
21
Zura Bio
ZURA
$322M
| $19.2M | 1.14% |
3,250,000
| – | – |
2026 Q1
1 quarter
|
|
22
Avalo Therapeutics
AVTX
$372M
| $18.8M | 1.12% |
1,018,319
+535,319
| +111% | +$8.46M |
2024 Q2
8 quarters
|
|
|
23
InflaRx
IFRX
$230M
| $16.4M | 0.97% |
+7,300,000
| New | +$13.7M |
2026 Q2
0 quarters
|
|
24
AN2 Therapeutics
ANTX
$134M
| $14.2M | 0.85% |
2,933,680
+599,967
| +26% | +$2.58M |
2026 Q1
1 quarter
|
|
|
25
DELISTED
Nuvalent
NUVL
| $12.4M | 0.74% |
100,000
-733,600
| -88% | -$78.9M |
2022 Q4
14 quarters
|
|
Similar funds
SH
TP
IAIM
Commodore Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Commodore Capital held 41 positions worth $1.68B, down 2.9% from $1.73B the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Commodore Capital withdrew a net $478M in Q2 2026, closing 8 positions and reducing 9 holdings. Its most notable exit was Erasca, an estimated $51.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.
Against the trend, Commodore Capital opened a new position in Tango Therapeutics worth $70.3M.
- Commodore Capital's largest Q2 2026 buy was Tango Therapeutics: 2,250,000 shares worth $70.3M.
- Commodore Capital added most to EyePoint Inc in Q2 2026, an estimated $23.7M increase.
- Commodore Capital's biggest Q2 2026 reduction was Nuvalent, cutting an estimated $78.9M.
- Commodore Capital fully exited Erasca in Q2 2026, selling an estimated $51.4M.
- Commodore Capital's ten largest holdings make up 68% of its $1.68B portfolio in Q2 2026.
- Commodore Capital opened 5 new positions and closed 8 in Q2 2026.
- Commodore Capital's portfolio value fell 2.9% quarter-over-quarter to $1.68B.
Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.